| First Author | Jha A | Year | 2022 |
| Journal | Viruses | Volume | 15 |
| Issue | 1 | PubMed ID | 36680164 |
| Mgi Jnum | J:350290 | Mgi Id | MGI:7662488 |
| Doi | 10.3390/v15010123 | Citation | Jha A, et al. (2022) Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice. Viruses 15(1) |
| abstractText | Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC(0-infinity) and Cl. AUC(0-last) increased and mean residence time, T(1/2), and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure. |
